Dicot

The Board of Directors of Dicot Pharma believes that a listing on Nasdaq First North will benefit Dicot's continued development, internationalization and competitiveness. The listing applies to both Dicot Pharma's share and warrant of series TO6.

All companies listed on First North must have a Certified Advisor (CA) approved by Nasdaq. Dicot Pharma has therefore engaged FNCA Sweden AB as CA to assist in the application for listing. The Board of Directors of the company believes that FNCA's deep experience in information provision, financial market regulations, and stock exchange related issues will be of great benefit to Dicot Pharma.

No action is required by the owners of shares and warrants in Dicot Pharma as trading after Nasdaq's approval will automatically be transferred to First North. This is expected to take place in November 2024, the exact date will be announced as soon as it is determined.

For further information, please contact:

Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: elin.trampe@dicotpharma.com

About Dicot Pharma AB

Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot's strategy is to develop LIB-01 under own auspices until phase 2a study and thereafter in partnership with larger, established pharmaceutical companies, finance and develop LIB-01 further to a registered pharmaceutical on the world market.

Dicot Pharma is listed on Spotlight Stock Market and has approximately 6,500 shareholders. For more information, please visit www.dicotpharma.com.